Details for Patent: 7,015,315

Which drugs does patent 7,015,315 protect, and when does it expire?

Patent 7,015,315 protects KYNAMRO and TEGSEDI and is included in two NDAs.

This patent has four hundred and ninety-nine patent family members in fourteen countries.

Summary for Patent: 7,015,315

Title:	Gapped oligonucleotides
Abstract:	Oligonucleotides and other macromolecules are provided which have increased nuclease resistance, substituent groups for increasing binding affinity to complementary strand, and subsequences of 2'-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H. Such oligonucleotides and macromolecules are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics.
Inventor(s):	Cook; Phillip Dan (Vista, CA), Monia; Brett P. (Carlsbad, CA)
Assignee:	ISIS Pharmaceuticals, Inc. (Carlsbad, CA)
Application Number:	08/465,866
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 7,015,315

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Kastle Theraps Llc	KYNAMRO	mipomersen sodium	SOLUTION;SUBCUTANEOUS	203568-001	Jan 29, 2013		DISCN	Yes	No				Y
Akcea Theraps	TEGSEDI	inotersen sodium	SOLUTION;SUBCUTANEOUS	211172-001	Oct 5, 2018		RX	Yes	Yes				Y

International Family Members for US Patent 7,015,315

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	154947
Austria	159025
Austria	160353
Austria	168561
Austria	186072
Austria	187771